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Objectives: Concise “synthetic” review of the state of the art of 
management of acute ischemic stroke.
Data Sources: Available literature on PubMed.
Study Selection: We selected landmark studies, recent clinical 
trials, observational studies, and professional guidelines on the 
management of stroke including the last 10 years.
Data Extraction: Eligible studies were identified and results lead-
ing to guideline recommendations were summarized.
Data Synthesis: Stroke mortality has been declining over the past 
6 decades, and as a result, stroke has fallen from the second to 
the fifth leading cause of death in the United States. This trend may 
follow recent advances in the management of stroke, which high-
light the importance of early recognition and early revascularization. 
Recent studies have shown that early recognition, emergency in-
terventional treatment of acute ischemic stroke, and treatment in 
dedicated stroke centers can significantly reduce stroke-related 
morbidity and mortality. However, stroke remains the second leading 
cause of death worldwide and the number one cause for acquired 
long-term disability, resulting in a global annual economic burden.
Conclusions: Appropriate treatment of ischemic stroke is essential 
in the reduction of mortality and morbidity. Management of stroke 
involves a multidisciplinary approach that starts and extends be-
yond hospital admission. (Crit Care Med 2020; 48:1654–1663)
Key Words: cerebral edema; penumbra; secondary neuronal injury
Treatment of acute ischemic stroke (AIS) consists of a multidisciplinary approach that more than ever requires the involvement of the critical care specialist. Before the 
1990s, treatment options for AIS were limited and mainly fo-
cused on symptomatic management, secondary prevention, and 
rehabilitation. Since then, the entire field was revolutionized 
by two major introductions. The first groundbreaking inno-
vation that dramatically transformed acute stroke care on the 
basis of a National Institutes of Neurological Disease and Stroke 
(NINDS) landmark study was the Federal Drug Administra-
tion’s (FDA) approval of IV tissue plasminogen activator (IV-
tPA) in 1995 (1). IV-tPA remained the mainstay of treatment 
for about 2 decades until 2015 when more sophisticated clin-
ical trials showed robust outcomes for endovascular therapy 
(EVT) (2). In the ICU, additional strategies aimed at optimizing 
patient’s physiology can interface between triage and/or revas-
cularization and discharge to rehabilitation.
EARLY DETECTION
Ischemic stroke can occur both in the community and in the hos-
pital and must be recognized by bystanders and/or providers. Early 
recognition activates a stroke-specific chain of survival (Table 1) 
(3). Stroke is a clinical diagnosis and several features of the patient’s 
clinical presentation can be used to identify stroke patients (Table 
2). Emergency Medical Systems are key in detection, triaging, and 
transport of stroke patients to receiving facilities.
PREHOSPITAL MANAGEMENT
Workflows and organized systems of care can efficiently reduce 
delays in time to treatments (Fig. 1). With the deployment of 
mobile stroke units (MSUs) equipped with CT scanners and 
telemedicine links, recognition of patients and administration 
of treatments may be more precise and efficient. Recent stud-
ies have shown that the implementation of MSUs has led to 
higher rates and reduced the time to IV-tPA administration and 
door-to-needle time compared with regular ambulance trans-
ports to emergency departments (EDs) (4–8). In theory, initi-
ation of therapies for intracerebral hemorrhage (ICH) such as 
blood pressure control and reversal of anticoagulation may also 
be implemented at the prehospital setting. In addition to clinical 
examination with conventional scales such as the Neurological 
Institutes of Health Stroke Scale (NIHSS), several prehospital 
scales and prompt recognition of severe strokes with large vessel 
occlusions (LVOs) have successfully been validated (Table 3) (9).
EMERGENCY DEPARTMENT, STROKE 
TEAMS, AND STROKE CODE
A stroke team can provide around the clock services for 
patients with stroke. Such team consists of physicians with 
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expertise in emergency medicine, vascular neurology/neu-
rosurgery, and radiologists; advance care providers, nurses, 
clinical pharmacists, therapists, and technicians; and labora-
tory personnel (10). In the ED, the efficiency and accuracy of 
recognition of stroke syndromes can be performed with tele-
medicine (11). In the Stroke Team Remote Evaluation Using a 
Digital Observation Camera (STRokE-DOC) study, two-way 
audiovisual consultation was superior to telephone-based con-
sultation in accurately identifying stroke patients, yielding a 
higher rate of IV-tPA administration with similar proportion 
in ICH but without effect on overall functional outcome (11). 
In the new era of recanalization for AIS with LVO (12), tele-
medicine systems have assisted in improving the recognition 
of stroke patients in need of endovascular therapies yielding to 
better functional outcomes and quality of life (13–16).
NEUROIMAGING
Conventional noncontrast CT can be implemented at the pre-
hospital level in specialized MSUs. A noncontrast CT scan has 
enough sensitivity to exclude hemorrhagic stroke such as sub-
arachnoid hemorrhage or ICH. The Alberta Stroke Program 
Early CT Score (ASPECTS) was designed to determine middle 
cerebral artery (MCA) infarct severity using a noncontrast 
head CT scan. One point gets subtracted from the maximum 
score of 10 for any sign of early ischemia in each of the 10 pre-
defined zones (ranges 0–10) (17) (Fig. 2). A patient with a 
high Rapid Arterial Occlusion Evaluation/NIHSS and normal 
looking brain or ASPECTS greater than 6 (Fig. 2A) means that 
infarction may not have set in and that revascularization strat-
egies may be implemented. Early signs of infarction on CT or 
lower ASPECTS are usually associated with poor prognosis and 
hemorrhagic conversion (Fig. 2B). Timing to CT and reporting 
of preliminary data should be under 20 minutes according to 
current guidelines. A CT-angiography (CT-A) can effectively 
detect LVO and provide useful information about the patient’s 
vascular anatomy and stroke etiology (Fig. 3) (18). Based on its 
rapid acquisition, many institutions now incorporate CT-per-
fusion (CT-P) technology to assess cerebral blood flow (CBF) 
by quantitative analysis of thresholds in time-to-maximum 
(T-max) transit and cerebral blood volumes. Quantification of 
ischemic “core” (CBF < 30%) and estimation of “penumbra” 
or tissue at risk (T-max > 6 s) can provide immediate informa-
tion for treatment decision-making. Clinical trials have shown 
that perfusion mismatch ratios of core/penumbra greater than 
1.8 may indicate the eligibility for EVT (Fig. 4) (19, 20). CT-P 
thresholds predicting infarction depend on the time from 
stroke symptom onset to imaging, time from imaging to reper-
fusion, and the quality of reperfusion (21). To this end, a pro-
cess that includes advanced imaging with CT-A/CT-P or MRI 
should not delay IV thrombolysis or EVT.
REVASCULARIZATION
The primary goal of advanced stroke management is revas-
cularization and limitation of secondary neuronal injury. IV 
thrombolysis and EVT are now available for selected patients.
IV Thrombolysis
The first landmark clinical trial that demonstrated the safety 
and efficacy of IV-tPA in 1995 transitioned the treatment for 
AIS from being purely symptomatic to a highly time-sensitive 
matter. It shows that if IV-tPA is administered within the first 
3 hours of symptom onset, patients are at least 30% more 
likely to have only minimal or no disability on the 90-day 
mark. Mortality difference between IV-tPA and placebo 
group was nonsignificant despite an increase in symptomatic 
hemorrhages in the treatment group (1). Although IV-tPA 
was the only AIS treatment until recently, the use of IV-tPA 
has been as low as 3.2–5.2% of all AIS patients in the United 
States (22). One major reason for the low treatment rate is 
the limited time window for IV-tPA. Based on the European 
study Thrombolysis with Alteplase 3 to 4.5 Hours after Acute 
TABLE 2. BEFAST, Detection of Stroke
Balance, acute or sudden onset of loss of balance or 
coordination
Eyes, blurred or unclear vision, double vision, and gaze prefer-
ence
Facial weakness or facial asymmetry
Arm and/or leg weakness
Speech difficulty/slurring of speech
Time is brain, time to activate stroke system and stroke clock
TABLE 1. The 8 D’s of Stroke Care
Detection: Involves recognizing the signs and symptoms of 
an acute stroke (BEFAST, Table 2)
Dispatch: Activation of emergency medical services. In most 
cases, this involves calling 911 or a stroke team
Delivery: Means prompt transport of the patient to a hospital, 
preferably a stroke center or to a setting in the hospital for 
further evaluation by a stroke team
Door: This refers to the arrival of the patient at the ED. Accord-
ing to recommendations from the National Institute of 
Neurological Disorders and Stroke, an assessment should 
be completed by an ED physician within 10 min of arriving in 
the ED
Data: Data collection includes results from laboratory tests and 
both a physical and a neurologic examination (Neurological 
Institutes of Health Stroke Scale)
Decision: Information, such as the type of stroke, last seen 
normal, and time from onset of symptoms, is considered be-
fore a treatment decision is made
Drug/device: Fibrinolytic therapy should be administered within 
4.5 hr of the onset of symptoms. Even if the patient is not a 
candidate for fibrinolysis, they may still qualify for endovascu-
lar therapy to remove mechanically a clot
Disposition: It is recommended that patients are admitted to 
an ICU or stroke unit within 3 hr of arrival in the ED
ED = emergency department.
See Table 2 for BEFAST expansion.
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Ischemic Stroke (ECASS-3), the American Heart Associa-
tion/American Stroke Association (AHA/ASA) extended the 
IV-tPA window from 3 to 4.5 hours in 2009 with additional 
exclusion criteria (22–24). This extension increased the utili-
zation of IV-tPA by up to 20% (25).
Recently, clinical trials suggested that imaging rather than 
known time of onset (last seen normal) can guide clinicians to 
treat patients using the time discrepancies of acute stroke show-
ing. Data from the European multicenter clinical trial MRI-
Guided Thrombolysis for Stroke with Unknown Time of Onset 
(WAKE-UP) suggest that almost 50% of wake-up strokes and 
daytime strokes of unknown onset are IV-tPA candidates when 
MRI criteria is used (26). However, cost, time spent in metal 
screening, and often far distance to the scanner are clear lim-
itations to its implementation. In the Thrombolysis Guided 
by Perfusion Imaging up to 9 
Hours after Onset of Stroke 
(EXTEND) clinical trial, CT-P 
imaging was used to assess the 
eligibility for IV-tPA and sug-
gested that the efficacy and 
safety of IV-tPA can extend up 
to 9 hours and that revascu-
larization can extend up to 24 
hours (27).
Tenecteplase, a newer throm-
bolytic agent with high fi-
brinogen specificity and long 
half-life, allowing it to be given 
as a single bolus, had prom-
ising results in recent clinical 
trials. The Tenecteplase versus 
Alteplase before Thrombectomy 
for Ischemic Stroke (EXTENT-
IA-TNK) trial demonstrated 
that tenecteplase administration 
resulted in a higher reperfusion 
rate and a better functional out-
come than alteplase in patients with AIS eligible for EVT (28, 29). 
Tenecteplase appears to be as efficacious, with a similar side-effect 
profile as alteplase when used in patients without LVO (30, 31). 
However, at this time, tenecteplase is not FDA-approved for IV 
thrombolysis in AIS patients and does not have the same level of 
recommendation by the AHA/ASA as alteplase. This could ex-
plain why many institutions have not adopted tenecteplase as a 
thrombolytic for AIS.
Endovascular Therapy
The FDA approval of IV-tPA has innovated the entire field of 
emergency neurology. However, up to 69% of stroke patients 
are ineligible to receive IV-tPA due to delayed hospital presen-
tation (32, 33). Over the last 3 years, the time window for AIS 
treatment has expanded thanks to EVT and has provided phy-
sicians with a stronger therapeutic arsenal. The success of EVT 
is measured by the degree or quality of revascularization. The 
Thrombolysis in Cerebral Infarction (TICI) scale is a tool to 
standardize the different degrees of reperfusion ranging from no 
perfusion (TICI 0) to complete perfusion (TICI 3) (Table 4) (34). 
TICI scores of 2B to 3 are usually regarded as successful reperfu-
sion. Previous studies failed to show improved results with EVT 
and diminished the initial optimism regarding intervention for 
AIS (35–37). However, the study design of those clinical trials 
was criticized for not requiring the image proof of LVO, using 
older technology for clot retrieval, and having prolonged stroke 
to puncture times. Since 2015, multiple trials have shown the ef-
ficacy of EVT in addition to standard medical care in improving 
the overall outcome of AIS patients with proximal MCA or in-
ternal carotid artery (ICA) occlusion when EVT was performed 
within either 6 hours (20, 38–41), 8 hours (42), or 12 hours (43) 
of symptom onset. A pooled meta-analysis demonstrated that 
modern EVT more than doubles the odds of a better functional 
Figure 1. Organization of stroke centers. EVT = endovascular therapy, IV tPA = IV tissue plasminogen activator.
TABLE 3. Rapid Arterial Occlusion 
Evaluation Scale
Facial palsy: Absent (0), mild (1), and moderate (2)
Arm motor impairment: Normal to mild (0), moderate (1), and 
severe (2)
Leg motor impairment: Normal to mild (0), moderate (1), and 
severe (2)
Head/gaze deviation: Absent (0) and present (1)
Aphasia: Performs tasks correctly (0), performs one task cor-
rectly (1), and performs neither task (2)
Agnosia: Recognizes his/her arm and deficit (0), does 
recognize his/her arm but not or deficit (1), and does not 
recognize his/her arm or deficit (2)
A score of ≥ 5, indicates higher likelihood of large vessel occlusion with 85% 
sensitivity and 68% specificity (9).
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outcome compared with standard therapy alone without any sig-
nificant difference in the mortality or risk of parenchymal hem-
orrhage at 90 days (2). Of 100 patients treated with EVT, 38 had 
a better functional outcome than the standard medical care. The 
number-needed-to-treat (NNT) for at least one patient to have 
a 1-point reduction on the modified Rankin Scale (mRS) is 2.6. 
The benefit of EVT remains substantial when only looked at the 
subset of patients that received IV-tPA prior to thrombectomy, 
and therefore, EVT should still be pursued after IV-tPA adminis-
tration. It is also suggested that EVT should not be withheld only 
on the basis of age, and patients older than 80 years may also ben-
efit from EVT (12). Two recent clinical trials showed that the time 
window can further be extended to 24 hours postsymptom onset 
if there is either mismatch between the clinical deficit and the in-
farct size or perfusion mismatch on imaging (19, 44). These trials 
are moving us away from an arbitrary clock time limit and trans-
forming the way we think of stroke and the “biological clock.” 
In most of these trials, the mean NIHSS was 16 or greater and 
further clinical trials are neces-
sary to investigate the efficacy 
of EVT in LVO presenting as 




Supplemental oxygen may be re-
quired if a patient’s saturation is 
less than 94%. Rapid neurologic 
deterioration and ensuing loss 
of consciousness with impair-
ment of reflexes that maintain 
the airway mandate definitive 
airway control. Failure to recog-
nize imminent airway loss may 
result in complications such as 
aspiration, hypoxemia, and hy-
percapnia, which may result in 
secondary neuronal injury. Hy-
perbaric oxygen was shown to 
either have no effect or be harm-
ful in AIS patients and should be 
avoided (45). For those critically 
ill AIS patients with respiratory 
failure and failure to wean off 
the ventilator, long-term trache-
ostomy may be required. The 
benefit of early tracheostomy is 
debatable but currently being 
studied under the Early Tra-
cheostomy in Ventilated Stroke 
Patients 2 (SETPOINT-2) pro-
spective clinical trial (Clinical-
Trials.gov: NCT02377167).
Blood Pressure
As part of cerebral autoregulation, blood pressure is com-
monly elevated during the acute phase of AIS, maximizing 
perfusion in the ischemic areas (46, 47). However, severe hy-
pertension can lead to hemorrhagic transformation of the 
infarct, hypertensive encephalopathy, as well as cardiopul-
monary and renal complications. Current AHA/ASA guide-
lines recommend permissive hypertension with a blood 
pressure goal of less than or equal to 220/120 mm Hg for 
the first 24–48 hours. Yet, these blood pressure variables 
only apply if the patient is not undergoing any acute inter-
vention such as IV-tPA or EVT. If the patient receives IV-
tPA, the risk of hemorrhagic transformation increases and 
the blood pressure should be lowered to less than or equal 
to 185/110 mm Hg prior to IV-tPA administration and to 
less than or equal to 180/105 mm Hg once IV-tPA has been 
given (48). Reperfusion injury and hemorrhagic transforma-
tion are of concern in the case of EVT; thus, blood pressure 
Figure 2. Alberta Stroke Program Early CT Score (ASPECTS). Scoring for each of the 10 zones. Each zone is 
graded either 1 (normal) or 0 (abnormal). The sum of all zones gives the ASPECTS. A, Normal looking brain with 
ASPECTS = 10. B, Brain with ischemic changes and ASPECTS less than 6. C = caudate, Ic = internal capsule, 
In = insular cortex, M = middle cerebral artery, P = putamen.
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must be closely monitored during and after EVT. A retro-
spective cohort study suggests maintaining an MAP goal of 
70–90 mm Hg during EVT to improve functional outcome 
(49). The current AHA/ASA guidelines recommend a post-
EVT blood pressure of less than or equal to 180/105 mm Hg 
(48). However, that guideline does not consider the degree 
of reperfusion achieved during EVT. In patients with suc-
cessful recanalization, defined as TICI 2b and TICI 3, the 
optimal postoperative blood pressure might be lower than 
that stated by the guidelines, to minimize the risk of reper-
fusion injury and ICH. A moderate blood pressure control 
with a systolic blood pressure goal less than or equal to 
160 mm Hg was shown to reduce the incidence of ICH and 
mortality, if successful EVT was achieved (50). Anadani et 
al (51) demonstrated that a postprocedural blood pressure 
range from 121 to 140 mm Hg was associated with improved 
functional outcome compared with higher blood pressure, if 
the patients had successful recanalization. Given these data, 
it appears that blood pressure after EVT should be individu-
alized based on the degree of recanalization.
Hypotension and hypovolemia should be avoided and 
corrected in patients with AIS. Etiologies for hypotension 
should ideally be sorted out with noninvasive modalities 
such as point-of-care ultrasound. While correcting hypo-
volemia, hypotonic solutions should be avoided due to the 
risk of increased edema formation. The usefulness of drug-
induced hypertension is not well established, so the random-
ized multicenter Safety and Efficacy of Therapeutic INduced 
HYPERTENSION in Acute Non-cardioembolic Ischemic 
Stroke (SETIN-HYPERTENSION) clinical trial (ClinicalTrials.
gov: NCT01600235) aims at determining the safety and ef-
ficacy of phenylephrine in patients with noncardioembolic 
stroke.
Glycemic Control
Evidence indicates that persistent in-hospital hyperglycemia 
during the first 24 hours after AIS is associated with worse 
outcomes compared with normoglycemia due to multiple po-
tential mechanisms, such as endothelial dysfunction, increased 
oxidative stress, and impaired fibrinolysis. However, in the 
NINDS funded Stroke Hyperglycemia Insulin Network Effort 
(SHINE) clinical trial, an intensive IV insulin protocol to 
achieve a systemic glucose between 80 and 130 mg/dL was not 
associated with favorable outcomes at 90 days compared with a 
standard regimen of insulin in a “sliding-scale” fashion to keep 
the glucose between 80 and 180 mg/dL (52). The intensive in-
sulin protocol was associated with significant hypoglycemic 
events and a higher level of care. To this end, it is reasonable to 
treat hyperglycemia to achieve blood glucose levels in a range 
of 140–180 mg/dL and to monitor closely to prevent hypogly-
cemia in patients with AIS.
Cerebral Edema
Large infarcts of the MCA or ICA are associated with high 
morbidity rates of up to 80%. Patients with large hemispheric 
infarcts (LHIs) are at increased risk of cerebral edema and fast 
neurologic deterioration that led to the term “malignant MCA 
infarction”(MMI) (53). Hypodensity seen in more than 50% 
of the MCA territory (Fig. 2B) or an infarct volume of greater 
than 145 cc within 14 hours of ictus are the most reliable pre-
dictors for a malignant course with increased intracranial pres-
sure, herniation, and need for decompressive hemicraniectomy 
(DHC) (54). The ultimate intervention to alleviate increased 
intracranial pressure and avoid herniation in LHI with signif-
icant edema is surgical decompression with DHC. Three Eu-
ropean clinical trials assessed the benefit of DHC in patients 
60 years and younger (55–57). A pooled analysis of these trials 
showed that DHC does not only reduce mortality by 50% but 
also improve long-term functional outcome (58). The NNT 
to avoid a death is 2 (mRS = 6), whereas the NNT to avoid 
death and the most severe to moderately severe disability is 4 
(mRS = 4–6). The proportion of patients alive with minimal-
to-moderate disability (mRS = 0–3) was increased from 21% 
to 43%. Viewed another way, DHC resulted in a 49% absolute 
risk reduction in death, and an absolute increase in the propor-
tion of patients rated as mRS = 2 of 12%, mRS = 3 of 10%, and 
mRS = 4 of 29% (58).
The DEcompressive Surgery for the Treatment of malig-
nant INfarction of the middle cerebral arterY (DESTINY-II) 
clinical trial assessed the outcome of DHC in patients older 
than 60. It demonstrated that DHC increases the probability of 
survival, but most survivors had significant disabilities (mRS 
= 4–5) (59). In all these trials, DHC was performed within 48 
hours, and currently, there is no indication for a “wait and see 
strategy” (e.g., waiting for neurologic deterioration or radio-
graphic midline shift). However, the ideal timing of DHC is 
still unclear and more data including standardized medical 
management are necessary. Furthermore, it remains debatable 
what the definition of a favorable functional outcome is and 
what degree of disability is regarded as acceptable. Additional 
Figure 3. CT-angiography demonstrating an abrupt occlusion of the 
patient’s left middle cerebral artery (arrow). L = left, R = right.
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surgical interventions that may be entertained in critically ill 
AIS patients are external ventricular drainage for the man-
agement of hydrocephalous and suboccipital craniectomy for 
posterior fossa/cerebellar infarcts with life-threatening cere-
bral edema.
In contrast to the three European DHC trials, the NINDS 
funded clinical trial Hemicraniectomy and durotomy upon de-
terioration from infarction-related swelling trial (HeADFIRST) 
did not find a mortality or morbidity benefit of DHC over a 
standardized medical treatment approach, which included 
normoglycemia (glucose < 200 mg/dL), permissive hyperna-
tremia (sodium < 155 mEq/dL), and hyperosmolar therapy 
(60). This raises the question if a conservative approach should 
be trialed prior to DHC.
Data on the use of hyperosmolar therapy in MMI are scarce 
and the evidence for reducing ICP is mainly extrapolated from 
the traumatic brain injury literature. Despite the lack of clear 
evidence in MMI, hyperosmolar therapy with mannitol or 
hypertonic saline (HTS) has been proposed to reduce cyto-
toxic edema (61, 62). There is no definitive data whether one 
hyperosmolar agent is superior to the other, and the choice 
can be guided by their individual side effects. Potential com-
plications of HTS use are fluid overload, pulmonary edema, 
hypokalemia, cardiac arrhythmias, hyperchloremic metabolic 
acidosis, acute kidney injury, and dilutional coagulopathy 
(63, 64). To avoid rebound edema, HTS should be gradually 
tapered and the serum sodium level should never be allowed to 
drop more than 10–12 mEq/L over 24 hours (63, 65). Potential 
complications of mannitol include acute kidney injury, hypo-
tension due to diuresis, rebound ICP, electrolytic imbalance 
(hypo-/hypernatremia), and acid/base disturbances.
Glyburide, an IV sulfonylurea has been proposed as a po-
tential agent for the management of cerebral edema due to its 
ionic properties at the sulfonylurea receptor-1-transient re-
ceptor potential melastatin-4 channel in neurons, astrocytes, 
and endothelium. The recent Safety and efficacy of intravenous 
glyburide on brain swelling after large hemispheric infarction 
(GAMES-RP) clinical trial demonstrated a substantial reduc-
tion in cerebral edema and midline shift without an impact 
on the outcomes (66). The industry-sponsored Phase 3 Study 
Figure 4. Mismatch ratio analysis of cerebral blood flow (CBF) by quantitative analysis of thresholds in time-to-maximum (T-max) to transit in a patient 
with a right middle cerebral artery occlusion. CBF in dark gray and T-max in light gray. A ratio of greater than 1.8 usually indicates eligibility for endovas-
cular therapy. RAPID = rapid processing of perfusion and diffusion image analysis system.
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to Evaluate the Efficacy and Safety of Intravenous BIIB093 
(Glibenclamide) for Severe Cerebral Edema Following Large 
Hemispheric Infarction (CHARM) clinical trial testing a sim-
ilar hypothesis with the sulfonylurea glibenclamide is un-
derway (ClinicalTrials.gov: NCT0286495).
Fever and Targeted Temperature Modulation
Observational studies have demonstrated the detrimental 
effects of fever on every outcome measure after stroke (67, 
68). It appears that the effect of fever (temperature core [Tc] 
> 37.5°C) is pertinent to severely brain injured patients in 
the ICU (69). Clinical studies have shown the potential effect 
of therapeutic hypothermia (Tc, 34–35°C) for the manage-
ment cerebral edema and intracranial hypertension. One 
study assessed the effect of targeted temperature modula-
tion on mortality and neurologic outcome in patients with 
LHIs but failed to show a difference with a trend toward bet-
ter functional outcome (70). Recently, the largest random-
ized clinical trial on therapeutic hypothermia after ischemic 
stroke European multicenter, randomized, phase III clinical 
trial of therapeutic hypothermia plus best medical treatment 
vs. best medical treatment alone for acute ischemic stroke 
(EURO-HYP) was stopped on the basis of futility. Similarly, 
the DEcompressive surgery Plus hypoTHermia for Space-
Occupying Stroke (DEPTH-SOS) study, using therapeutic hy-
pothermia and DHC after LHIs, was terminated early on the 
basis of harm in the therapeutic hypothermia arm (71). The 
ongoing Impact of Fever Prevention in Brain Injured Patients 
(INTREPID) randomized clinical trial is testing the hypo-
thesis that early fever prevention to achieve normothermia 
(Tc = 37°C) after stroke is associated with improved outcomes 
(ClinicalTrials.gov: NCT02996266). Although there is paucity 
of high-quality data in support of fever control after ischemic 
stroke, it is recommended that patients with severe brain in-
jury and fever refractory to medical therapy receive some de-
gree of fever prevention while in the ICU (72).
Rehabilitation
Early mobilization is thought to be of great importance in 
order to maximize functional recovery and independence after 
AIS. Animal models have shown that neuroplasticity and cor-
tical reorganization, promoting functional improvement, peak 
7–14 days after stroke and last for about 1 month (73). Early 
rehabilitation is thought to enhance further this dynamic post-
stroke phase and help patients to gain compensatory mecha-
nisms for remaining disabilities. Data show that even in ICU 
patients, early rehabilitation and intensity of rehabilitation 
sessions were associated with a better functional outcome 
(74). Yet, the optimal intensity and timing of early mobiliza-
tion remain uncertain. The phase-III A Very Early Rehabilita-
tion Trial after stroke (AVERT) clinical trial demonstrated that 
very early mobilization (< 24 hr after stroke) with frequent and 
prolonged rehabilitation sessions resulted in reduced favorable 
outcome. However, the dose-response analysis showed that 
short and frequent mobilizations may be beneficial early after 
acute stroke, whereas prolonged out-of-bed sessions reduce 
the odds of a good outcome (75). Furthermore, randomized 
controlled trials are needed to clarify those uncertainties.
Nutrition
As in the case with all critically ill neurologic patients, en-
teral feeding should be started within 48 hours to avoid pro-
tein catabolism and malnutrition. A small-bore nasoduodenal 
feeding tube may reduce the risk of aspiration events. Assess-
ment of speech and swallowing function is imperative in AIS 
patients to determine the need for long-term enteral nutrition 
with percutaneous enteric gastrostomy.
Risk Factor Modification (Secondary Prevention)
Classification of AIS subtype/etiology is based on the defi-
nitions used in the multicenter Trial of Org 10172 in Acute 
Stroke Treatment and include the following: 1) large-artery 
atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion, 
4) stroke of other determined etiology, and 5) stroke of un-
determined etiology (cryptogenic) (76). A thorough workup 
consisting of vascular imaging, MRI, transthoracic echo-
cardiogram with bubble assessment (for shunt evaluation), 
lipid panel, and hemoglobin A1C, among others, is required 
to determine the underlying etiology and tailor the appro-
priate secondary stroke prevention. Antiplatelet therapy is 
an important cornerstone of treatment for the prevention of 
stroke and transient ischemic attacks (TIAs). Aspirin is the 
most commonly used agent, since it is relatively safe, cheap, 
and widely available. It reduces the risk of recurrent stroke 
within the acute phase of 2–4 weeks post-AIS if administered 
within 48 hours of onset (77, 78). A meta-analysis of 16 sec-
ondary prevention trials concluded that aspirin reduces the 
risk of recurrent ischemic stroke by 22% and has the strongest 
effect in the early weeks after AIS (79, 80). The P2Y12 inhib-
itor clopidogrel is another commonly used antiplatelet agent 
in AIS. The Clopidogrel with Aspirin in Acute Minor Stroke 
or Transient Ischemic Attack (CHANCE) trial, a study with 
primary Asian ethnicity, demonstrated a reduction of 90-day 
TABLE 4. Thrombolysis in Cerebral Infarction 
Scale
Grade  Radiographic Features
0 No perfusion beyond the point of occlusion
1 Penetration with minimal perfusion. Contrast passes 
the obstruction but fails to visualize the entire 
cerebral bed beyond the point of obstruction
2 Partial perfusion. Contrast passes the obstruction 
and visualized the cerebral bed past the obstruc-
tion. However, flow of contrast in the distal bed  
is slower than other, nonobstructed vessels
2A Only < 2/3 of entire vascular territory is visualized
2B Complete visualization of the vascular territory but 
with slower filling than normal
3 Complete perfusion. Entire vascular territory is 
visualized with normal flow
Higashida et al (34).
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stroke incidence after minor strokes (NIHSS < 4) or TIAs with 
the combination therapy aspirin and clopidogrel (dual anti-
platelet therapy) for 21 days poststroke when compared with 
aspirin alone, without demonstrating an increase in hemor-
rhages (81). The American Clopidogrel and Aspirin in Acute 
Ischemic Stroke and High-Risk TIA (POINT) trial was able 
to reproduce those results in a more ethnically diverse co-
hort (82). Finally, cardioembolic strokes that account for up 
to 40% may warrant treatment with full anticoagulation to 
prevent recurrence. However, depending on the infarct size, 
full anticoagulation could result in hemorrhagic transforma-
tion in the immediate poststroke period. For these patients, an 
initial strategy of antiplatelet therapy bridging to full antico-
agulation within 10–14 days of stroke is widely accepted and 
based on clinical trials that demonstrated the risk of stroke 
recurrence within this time frame is minimal (48, 83, 84). In 
certain patients with embolic strokes of undetermined source, 
long-term cardiac monitoring may be indicated to increase 
the yield of diagnosing paroxysmal atrial fibrillation (85).
Statins are the drug of choice for dyslipidemia, which is an 
important risk factor for atherosclerotic disease. In recent years, 
studies showed that statins have a pleiotropic effect beyond 
lowering cholesterol including being antithrombotic, anti-in-
flammatory, and endothelial protective (86). The The Stroke 
Prevention by Aggressive Reduction of Cholesterol Levels 
(SPARCL) clinical trial assessed the effect of statins on sec-
ondary stroke prevention and demonstrated that high-intensity 
atorvastatin reduces both fatal and nonfatal stroke recurrence 
with the highest effect in the carotid stenosis group. The study 
included patients with small-vessel occlusion, large vessel ath-
erosclerosis, and unknown etiology excluding cardioembolic 
strokes (87). Recent clinical trials suggest that cholesterol low-
density-lipoprotein level ~70 mg/dL is optional to decrease 
stroke recurrence (88). Although some studies showed an 
increased risk of ICH with statin therapy (89, 90), other pooled 
analyses failed to demonstrate that relationship (91, 92).
CONCLUSIONS
Over the last few decades, multiple new innovations have 
introduced a new era of vascular neurology and included more 
patients for acute treatment, leading to improved outcome. 
Despite these groundbreaking changes, the constant decline in 
stroke mortality has slowed down and even reversed in sev-
eral states of the United States (93). One of the reasons for this 
trend is the rising number of patients with stroke risk factors 
like diabetes, hypertension, and hyperlipidemia. In the future, 
the focus should shift more toward patient education and pre-
vention in order to reduce the incidence of stroke leading to 
severe disability or death.
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